Navigation Links
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Date:3/28/2008

VANCOUVER, March 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that results from an investigator-sponsored Phase II study, in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), showed that a combination therapy of verteporfin (Visudyne(R)) followed by bevacizumab (Avastin(R)) reduced, by half, the number of treatments required during the first six months to gain similar visual acuity compared to Avastin monotherapy. In addition, 30% of the patients treated using the combination therapy required only a single combination treatment compared to Avastin monotherapy, with which all patients required additional treatments.

Visudyne therapy is approved for the treatment of age-related macular degeneration (AMD) in patients with predominantly classic subfoveal choroidal neovascularization. QLT Inc. is the manufacturer of Visudyne.

Dr. Michael Potter, the investigator-sponsor of the verteporfin and bevacizumab (VIA) clinical trial, which was supported by QLT, presented results today at the 31st Annual Macula Society Meeting that is being held this week in Florida. The objective of the VIA study was to determine whether Visudyne, at low or very low fluence rates, in combination with Avastin, reduces the average number of treatments required, compared to Avastin alone.

"We are very pleased with the clinical outcomes of this study. Our goal was to see if it is possible to minimize the number of treatments while maintaining or improving visual acuity in patients with CNV secondary to AMD. At six months, virtually all the patients treated with the Visudyne combination therapy gained visual acuity with half the number of treatments required with Avastin monotherapy. These results are encouraging, and more research continues to be done to evaluate the benefits of combination therapy in terms of helping patients improve their vision and also reducing the cost of t
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
2. MRIs high false positive rate has little impact on womens choice of preventive mastectomy
3. AcroMetrix Announces Launch of First Liquid MRSA Positive Control
4. Make Your Mammogram a Positive Experience: Author Offers Guidelines and Tips to Change Womens Negative Attitudes Toward Mammograms
5. QLT announces positive FDA action on Aczone(TM)
6. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
7. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
8. Ibuprofen destroys aspirins positive effect on stroke risk
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Positive results from phase 1 clinical trials of cuprindro
11. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Newswire/-SentinelleMedicalInc.,aleadingmanufactur...launchesasuiteofnewleadingedgeclinicalapplications...year,sRadiologicalSocietyofNorthAmerica(RSNA)annua...A).Theapplicationsleveragetheuniquehighqualityimag...sandsupportmultipleimagingmodalitiesformulti-param...
(Date:11/25/2009)...25/PRNewswire/--TheBayAreaAirQualityManagementDist...he Air Alert forThursday,November26,2009wh...olidfuel,bothindoorsandoutdoors. ,, "Cold,still...,"saidJackBroadbent,executiveofficeroftheAirDistri...ftheirneighborsandfellowcommunitymembersthisThanks...
(Date:11/25/2009)...y that grew out of a collaboration between UCLA en...e to the nearly 10 million Americans who suffer fr... as hardening of the arteries, peripheral arterial...in which narrowed arteries reduce blood flow to th...r vascular disease, heart attack and stroke, and i...
(Date:11/25/2009)... Evaluation and treatment clinics to resume Monday...cus) November 25, 2009 -- Centegra Health System i... vaccine shots at four Centegra Primary Care (CPC)...cine has arrived. The clinics are at CPC sites in ...ill be open as follows: ,   From 4:30 ...
(Date:11/25/2009)...Newswire/-- MISSIONSkincare ®isproudtosupport...artofGNC,sannualSt.Jude ThanksandGiving campaign,$...w SUPER-C(TM)LipBalm willbedonatedtoSt.Jude.Addit...or$10donationatcheckoutatoneoftheir5,000+retailloc...forSt.Judeduringtheir2009 ThanksandGiving campaign...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2
... OCTOBER 16 WORLD-RENOWNED SCIENTISTS WILL CONVENE...EASE, MEMORY AND AGING, MORGANTOWN, W.Va., Aug. 2...hette Rockefeller Neurosciences Institute,(BRNI) l...nal scientists who are advancing research on Alzhe...
... The Drug Information Asso...cal Imaging Contrast Agent Association (MICAA), th...s (CORAR), PhRMA, and the American Medical Informa...maceutical Products (October 2-3; Bethesda, MD) , ...
...NCOUVER, Aug. 26 /PRNewswire-FirstCall/ - QLT Inc.... USA, Inc., its wholly-owned subsidiary,has entere... Benckiser,Pharmaceuticals Inc. for its Atrigel(R)...se agreement and related asset,purchase agreement,...
...ENZHEN, China Aug. 25 /Xinhua-PRNewswire-FirstCall... MR ), a leading developer, manufacturer,and marke...lect historical,financial figures converted from C...fective April 1, 2008.,Accordingly, Mindray has is...
...nadian study suggests cautions fail to alert docs ... , MONDAY, Aug. 25 (HealthDay News) -- Safety war...iors with dementia. But the overall use of the dru...te 2002 and June 2005, Health Canada issued three ...
...nter for Cell Phone Applications in Healthcare (C-... Members, BOSTON, Aug. 25 Medical Records Instit...lications in Healthcare (C-PAHC), a,membership-bas...0080825/NEM092LOGO ), C-PAHC envisions the devel...
Other Medicine News:Health News:Pioneering Neurosciences Institute Sets Date for Dedication of New Facility and First-Ever International Forum on Memory and Memory Disorders 2Health News:Pioneering Neurosciences Institute Sets Date for Dedication of New Facility and First-Ever International Forum on Memory and Memory Disorders 3Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 2Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 3Health News:QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. 2Health News:QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. 3Health News:Mindray Releases Historical Financial Results Converted into US Dollar Terms 2Health News:Antipsychotic Drug Use Up in Elderly Despite Warnings 2Health News:Medical Records Institute Unveils Platform for Studying Cell Phone Applications in Healthcare 2
(Date:11/25/2009)...FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),amedicald...ydisruptivesurgicaltreatmentsforthespine,announced...r30,2009,at5:30p.m.ET/2:30p.m.PT.Theconferencecall...theCompany,sproductsandwillincludecommentsfrommana...dial-innumbersare1-877-407-4018fordomesticcallersa...
(Date:11/25/2009)...-Reportlinker.comannouncesthatanewmarketresearchre...ugDelivery-USMarketTrends&Analysis http://www...y---US-Market-Trends--Analysis.html ,, TheUSin...ftherapeuticapplicationsfromthedeliveryofconventio...rapeuticdrugs.Thefutureofthetechnologyhingesontoth...
(Date:11/25/2009)...PRNewswire/-- ChemoCentryx,Inc.,announcedtodaytha...theProspectiveRandomizedOralTherapyEvaluationinCro...entswithmoderate-to-severeCrohn,sdiseasedemonstrat...ityprofile.Thestudydemonstratedevidenceofclinicale...70-pointdecreaseintheCrohn,sDiseaseActivityIndex(C...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Embarrassing illnesses no bar to information sharing 52625 1Embarrassing illnesses no bar to information sharing 52625 2URI researcher sheds light on man eating squid 3B finds them timid non threatening 9340 1URI researcher sheds light on man eating squid 3B finds them timid non threatening 9340 2URI researcher sheds light on man eating squid 3B finds them timid non threatening 9340 3Caraco Pharmaceutical Laboratories Ltd Announces Filing of Purported Class Action Lawsuits 52622 1Caraco Pharmaceutical Laboratories Ltd Announces Filing of Purported Class Action Lawsuits 52622 2
...Biopure Corporation,(Nasdaq: BPUR ) announced tod...RC) has submitted a new protocol for review by the...clinical trial of Hemopure(R),[hemoglobin glutamer...f,operational casualties with severe traumatic hem...fusions. The proposed trial hypotheses is that,for...
...ts To Breathe Without Ventilator Clini...AND, June 18 Synapse Biomedical Inc., (http://www...ceived approval from,the U.S. Food and Drug Admini...r-dependent Spinal Cord Injury (SCI) patients who ...he FDA,s approval, SCI patients and,their caregive...
Other Medicine Technology:U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R) 2U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R) 3Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications 2Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications 3Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications 4Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications 5Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications 6
BANGOLINI LENSES Nos. 2 and 4 IN CASE
BD Visitec IOL Manipulator (Fenzl)
Hunkeler Lens Manipulator
Hunkeler IOL Manipulator
Medicine Products: